Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20336550 | 0.86 | CYP2D6 (0.50) | CYP2D6KMT2ALMNASRCMAPK1 | |
| SCHEMBL10162836 | 0.86 | CYP2D6 (0.50) | CYP2D6KMT2ALMNASRCMAPK1 | |
| SCHEMBL20336552 | 0.86 | CYP2D6 (0.50) | CYP2D6KMT2ALMNASRCMAPK1 | |
| SCHEMBL18261175 | 0.83 | CYP2D6 (0.46) | CYP2D6KMT2ALMNASRCMAPK1 | |
| SCHEMBL31447452 | 0.83 | CYP2D6 (0.48) | CYP2D6POLB | |
| SCHEMBL14359915 | 0.82 | CYP2D6 (0.47) | CYP2D6KMT2AMAPK1CHRM2CHRM4 | |
| SCHEMBL23872457 | 0.82 | CYP2D6 (0.61) | CYP2D6KMT2ALMNASRCMAPK1 | |
| SCHEMBL499471 | 0.82 | CYP2D6 (0.61) | CYP2D6KMT2ALMNASRCMAPK1 | |
| SCHEMBL4612358 | 0.82 | CYP2D6 (0.61) | CYP2D6KMT2ALMNASRCMAPK1 | |
| SCHEMBL4611322 | 0.82 | CYP2D6 (0.61) | CYP2D6KMT2ALMNASRCMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115175887-B | Phenol derivatives and their use in medicine | 天地恒一制药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115175887-A | Phenol derivative and application thereof in medicine | 天地恒一制药股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-105143170-B | For treating the aromatic compounds of pulmonary fibrosis, liver fibrosis, fibrosis of skin and cardiac fibrosis being substituted | 普罗米蒂克医药SMT有限公司 | 2019-11-08 | — | — | CN | disclosed |
| CN-105997967-B | Compound and composition for treating cancer | 普罗米蒂克医药SMT有限公司 | 2019-08-23 | — | — | CN | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102292319-A | Novel substituted octahydrocyclopenta(C)pyrrol-4-amines as calcium channel blockers | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CYP2D6 617/4885KMT2A 3363/4885LMNA 598/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CYP2D6 617/4885KMT2A 3363/4885LMNA 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.